Atea Pharmaceuticals (AVIR) Other financing activities (2020 - 2026)
Atea Pharmaceuticals (AVIR) posted quarterly Other financing activities of $132000.0 for Q1 2026, down 4.35% year-over-year from $138000.0 in Q1 2025, and down 7.69% quarter-over-quarter from $143000.0 in Q4 2025.
Powered by 
Analysis
Atea Pharmaceuticals (AVIR) Other financing activities (2020 - 2026) Analysis & Trends
Atea Pharmaceuticals' Other financing activities history runs 6 years deep, the most recent figure standing at $132000.0 for Q1 2026.
- In Q1 2026, Other financing activities fell 4.35% year-over-year to $132000.0; the TTM figure through Mar 2026 stood at $338000.0 (up 32.55% YoY), while the FY2025 annual figure was $201000.0, down 24.72% from the prior year.
- Other financing activities for Q1 2026 stood at $132000.0, down from $143000.0 in the prior quarter.
- The five-year high for Other financing activities was $223000.0 in Q1 2022, with the low at $63000.0 in Q3 2025.
- The 5-year median for Other financing activities is $139000.0 (2022), against an average of $136300.0.
- The sharpest annual moves came in 2022 and 2024: Other financing activities plunged 82.39% in 2022, then gained 27.17% in 2024.
- Atea Pharmaceuticals' Other financing activities stood at $140000.0 in 2022, then sank by 34.29% to $92000.0 in 2023, then increased by 27.17% to $117000.0 in 2024, then climbed by 22.22% to $143000.0 in 2025, then slipped by 7.69% to $132000.0 in 2026.
- Business Quant data shows AVIR's Other financing activities at $132000.0 in Q1 2026, $143000.0 in Q4 2025, and $63000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Atea Pharmaceuticals | 467.50 Mn | 467.50 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 871,000.00 |
| Sep 30, 2025 | 63,000.00 |
| Mar 31, 2025 | 138,000.00 |
| Sep 30, 2024 | 117,000.00 |
| Mar 31, 2024 | 150,000.00 |
| Sep 30, 2023 | 92,000.00 |
| Mar 31, 2023 | 165,000.00 |
| Sep 30, 2022 | 140,000.00 |
| Mar 31, 2022 | 223,000.00 |
| Dec 31, 2021 | 142,000.00 |
| Sep 30, 2021 | 795,000.00 |
| Jun 30, 2021 | 57,000.00 |
| Mar 31, 2021 | 471,000.00 |
| Dec 31, 2020 | 317.58 Mn |